Spots Global Cancer Trial Database for lymphoid malignancies
Every month we try and update this database with for lymphoid malignancies cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT00406809 | Chronic Lymphoi... Lymphoid Malign... Non-Hodgkin's L... Follicular Lymp... Mantle Cell Lym... Peripheral T-ce... | ABT-263 | 18 Years - 99 Years | AbbVie | |
| A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies | NCT01013818 | Lymphoid Malign... | HGS1029 | 18 Years - | Human Genome Sciences Inc. | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| Campath-1H and Allogeneic Blood Stem Cell Transplantation for Lymphoid Malignancies | NCT00038883 | Leukemia, Lymph... Leukemia, Lymph... Lymphoma, Low-G... Lymphoma, T-Cel... Lymphoma, B-Cel... | Campath-1H | 15 Years - 60 Years | M.D. Anderson Cancer Center | |
| Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies | NCT01421173 | Lymphoma | Vorinostat Gemcitabine Busulfan Melphalan Stem Cell Infus... Rituximab G-CSF Palifermin Dexamethasone a... | 12 Years - 65 Years | M.D. Anderson Cancer Center | |
| Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies | NCT01435447 | Lymphoid Malign... | FLu-Bu-Cy | 16 Years - 60 Years | Shanghai Jiao Tong University School of Medicine | |
| A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies | NCT01705847 | Lymphoid Malign... | GS-9820 | 18 Years - | Gilead Sciences | |
| Ph2 NK Cell Enriched DCIs w/wo RLR9 Agonist, DUK-CPG-001 From Donors Following Allogeneic SCT | NCT02452697 | Myeloid Maligna... Lymphoid Malign... | NK Cell enriche... NK-DLI + DUK-CP... | 18 Years - | Duke University | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| RTA 402 in Advanced Solid Tumors or Lymphoid Malignancies | NCT00508807 | Lymphoid Malign... Solid Tumors | RTA 402 | 18 Years - | M.D. Anderson Cancer Center | |
| Intrathecal Rituximab in Lymphoid Malignancies Involving Central Nervous System | NCT01596127 | Leukemia Lymphoid Malign... Metastatic Mali... | Intrathecal Rit... | 3 Years - | M.D. Anderson Cancer Center | |
| Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies | NCT01947140 | Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Pralatrexate Romidepsin | 18 Years - | Columbia University | |
| Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders | NCT00992732 | Lymphoid Malign... Lymphoprolifera... | HQK-1004 Valganciclovir ... | 3 Years - | HemaQuest Pharmaceuticals Inc. | |
| RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | NCT00529438 | Advanced Solid ... Lymphoid Malign... | Bardoxolone met... | 18 Years - | Biogen | |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | NCT01263899 | Hodgkin Lymphom... Mantle Cell Lym... Indolent Lympho... | SB1518 | 18 Years - | S*BIO | |
| Rituximab in Addition to Autologous Transplantation With BEAM for Patients With Lymphoid Malignancies | NCT00472056 | Lymphoma | Carmustine Etoposide Cytarabine Melphalan Rituximab | - 80 Years | M.D. Anderson Cancer Center | |
| Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies | NCT00820508 | Hematological D... Lymphoid Malign... | CHR-2845 | 18 Years - | Chroma Therapeutics | |
| A Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | NCT01263899 | Hodgkin Lymphom... Mantle Cell Lym... Indolent Lympho... | SB1518 | 18 Years - | S*BIO | |
| A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment | NCT02951117 | Multiple Myelom... | Venetoclax ABBV-838 Dexamethasone | 18 Years - 99 Years | AbbVie | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00383994 | Lymphoma Leukemia Transplantation... Lymphoid Malign... Disorder Relate... | GM-CSF Rituximab NK Cell Infusio... | - | M.D. Anderson Cancer Center | |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | NCT05371054 | Lymphoma Non-Hodgkin Lym... NHL Hematologic Mal... Lymphoid Malign... | Vysis LSI MYC B... venetoclax VIP152 prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | NCT00410982 | Leukemia Lymphoma Myeloma | Busulfan Gemcitabine Melphalan Hematopoietic C... Rituximab for P... Palifermin | 18 Years - 69 Years | M.D. Anderson Cancer Center | |
| Roll Over Study to Provide Idelalisib to Participants Previously Treated With the Investigational PI3Kδ Inhibitor, GS-9820 | NCT02739360 | Lymphoid Malign... | Idelalisib | 18 Years - | Gilead Sciences | |
| RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | NCT00529438 | Advanced Solid ... Lymphoid Malign... | Bardoxolone met... | 18 Years - | Biogen | |
| RTA 402 in Patients With Advanced Solid Tumors or Lymphoid Malignancies | NCT00529438 | Advanced Solid ... Lymphoid Malign... | Bardoxolone met... | 18 Years - | Biogen | |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | NCT01998035 | Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Romidepsin Oral 5-Azacitid... | 18 Years - | Columbia University | |
| Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies | NCT05371054 | Lymphoma Non-Hodgkin Lym... NHL Hematologic Mal... Lymphoid Malign... | Vysis LSI MYC B... venetoclax VIP152 prednisone | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| CD34 Selection Using the Automated CliniMACS Prodigy | NCT06047886 | AML ALL Lymphoid Malign... Myelodysplastic... CML Primary Myelofi... | Infusion of CD3... | 4 Weeks - 75 Years | University of Alabama at Birmingham | |
| A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies | NCT00741871 | Lymphoma, Malig... Hodgkin's Lymph... B Cell Lymphoma | SB1518 | 18 Years - | S*BIO | |
| Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies | NCT01998035 | Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym... | Romidepsin Oral 5-Azacitid... | 18 Years - | Columbia University | |
| A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies | NCT01703572 | Relapsed or Ref... | OMP-52M51 | 18 Years - 90 Years | Mereo BioPharma | |
| Allogeneic Hematopoietic Stem Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-thymocyte Globulin for Older Patients With Relapsed Lymphoid Malignancies | NCT01566656 | Haemato-lymphoi... | total lymphoid ... | 50 Years - 66 Years | Nantes University Hospital | |
| Intra-Osseous Co-Transplant of UCB and hMSC | NCT02181478 | Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Myelofibrosis Relapsed Non-Ho... Refractory Non-... Hodgkin Lymphom... Refractory Hodg... Relapsed Chroni... Refractory Chro... Lymphoid Malign... Chronic Myeloge... | cyclophosphamid... fludarabine pho... total-body irra... cyclosporine mycophenolate m... umbilical cord ... mesenchymal ste... | 18 Years - 75 Years | Case Comprehensive Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
